title: Haemostatic factors and lipoprotein (a) in three geographical areas in Finland: the Finrisk Haemostasis Study.
abstract: BACKGROUND
  An increasing volume of evidence suggests that haemostatic factors play a role in the risk of coronary heart disease. It is not known, however, whether between-population differences in haemostatic factors correspond with the differences in mortality related to coronary heart disease. We examined this question in Finland, where, in North Karelia (in the eastern part of the country), the mortality from coronary heart disease is 1.5-1.7 times higher than that in southwestern areas.
  
  
  METHODS
  A random sample of 3000 people aged 45-64 years was drawn from the population registers of North Karelia, of the area surrounding Turku and Loimaa in southwestern Finland and of the Helsinki area in southern Finland. Of the 3000 people approached, 79.6% took part in the study. differences in coronary heart disease mortality and morbidity.
  
  
  RESULTS
  Factor-VII coagulant activity was significantly higher in North Karelia than in the other areas (P = 0.0008). The fibrinogen level was also higher in North Karelia, although the difference was significant only among non-smokers (P = 0.02). Levels of factor-VII antigen, plasminogen and lipoprotein (a) did not differ between the areas. Within North Karelia, the levels of both factor-VII coagulant activity, and factor-VII antigen were higher in rural areas than in urban areas. Levels of factor-VII coagulant activity, factor-VII antigen and plasminogen were higher in women than in men and increased with age in women but not in men. The fibrinogen level increased with age in both sexes.
  
  
  CONCLUSIONS
  These baseline findings of the Finrisk Haemostasis Study demonstrate that the geographical differences in levels of factor-VII coagulant activity and fibrinogen in Finland are consistent with the population
authors.affiliation: Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland.
authors.forename: V V
authors.initials: VV
authors.lastname: Salomaa
authors.forename: V P
authors.initials: VP
authors.lastname: Rasi
authors.forename: E M
authors.initials: EM
authors.lastname: Vahtera
authors.forename: J
authors.initials: J
authors.lastname: Pekkanen
authors.forename: M
authors.initials: M
authors.lastname: Pursiainen
authors.forename: M
authors.initials: M
authors.lastname: Jauhiainen
authors.forename: E
authors.initials: E
authors.lastname: Vartiainen
authors.forename: C P
authors.initials: CP
authors.lastname: Ehnholm
authors.forename: G
authors.initials: G
authors.lastname: Myllylä
mesh_terms: D017677:Age Distribution; D000941:Antigens / Q000378:metabolism; D003327:Coronary Disease / Q000453:epidemiology* / Q000401:mortality / Q000503:physiopathology*; D003710:Demography; D005167:Factor VII / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D005387:Finland / Q000453:epidemiology; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D015994:Incidence; D017270:Lipoprotein(a) / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism*; D012307:Risk Factors; D017678:Sex Distribution; D015996:Survival Rate
chemical_list: D000941:Antigens; D017270:Lipoprotein(a); C031500:factor VII related antigen; D005167:Factor VII; D005340:Fibrinogen; D010958:Plasminogen